Neha Bhooshan1, Paul N Staats1, Amy M Fulton2, Josephine L Feliciano1, Martin J Edelman3. 1. University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD, 21201, USA. 2. University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD, 21201, USA; Baltimore Veterans Administration Medical Center, Baltimore, MD 21201, USA. 3. University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD, 21201, USA. Electronic address: medelman@umm.edu.
Abstract
BACKGROUND: Elevated COX-2 expression has been correlated with inferior outcome in NSCLC. COX-2 catalyzes the transformation of arachidonate to PGE2. We and others have demonstrated that PGE2 induces proliferation and metastatic spread and immunosuppression through the G protein-coupled EP4 receptor. We hypothesized that EP4 expression on malignant cells would correlate with outcome and patterns of relapse after treatment of LANSCLC stage IIIA (7th edition, N2+). METHODS: Tissue specimens from 41 pts treated for LANSC at UMGCC were obtained. A tissue microarray was prepared and examined for EP4 expression. Intensity of staining was scored semi-quantitatively as 0-4 in both the nuclear and cytoplasmic compartments by a pathologist blinded to the clinical data. RESULTS: EP4 nuclear staining 0-1 vs. 2+ was associated with overall survival, (OS) (44.3 vs. 18 mo; HR=0.41, p=0.024) and numerically superior progression free survival (PFS) (16.4 vs. 10.2 mo, p=0.16). EP4 cytoplasmic staining did not correlate with OS (0-1 vs. 2+, 23.8 vs. 28.8 mo; HR=1.2, p=0.81). Relapse pattern (no relapse or local vs. systemic) did not correlate with EP nuclear staining (p=1.0, X2). CONCLUSIONS: This is the first clinical study of EP4 expression in lung cancer. There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year.
BACKGROUND: Elevated COX-2 expression has been correlated with inferior outcome in NSCLC. COX-2 catalyzes the transformation of arachidonate to PGE2. We and others have demonstrated that PGE2 induces proliferation and metastatic spread and immunosuppression through the G protein-coupled EP4 receptor. We hypothesized that EP4 expression on malignant cells would correlate with outcome and patterns of relapse after treatment of LANSCLC stage IIIA (7th edition, N2+). METHODS: Tissue specimens from 41 pts treated for LANSC at UMGCC were obtained. A tissue microarray was prepared and examined for EP4 expression. Intensity of staining was scored semi-quantitatively as 0-4 in both the nuclear and cytoplasmic compartments by a pathologist blinded to the clinical data. RESULTS:EP4 nuclear staining 0-1 vs. 2+ was associated with overall survival, (OS) (44.3 vs. 18 mo; HR=0.41, p=0.024) and numerically superior progression free survival (PFS) (16.4 vs. 10.2 mo, p=0.16). EP4 cytoplasmic staining did not correlate with OS (0-1 vs. 2+, 23.8 vs. 28.8 mo; HR=1.2, p=0.81). Relapse pattern (no relapse or local vs. systemic) did not correlate with EP nuclear staining (p=1.0, X2). CONCLUSIONS: This is the first clinical study of EP4 expression in lung cancer. There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year.
Authors: M Bhattacharya; K Peri; A Ribeiro-da-Silva; G Almazan; H Shichi; X Hou; D R Varma; S Chemtob Journal: J Biol Chem Date: 1999-05-28 Impact factor: 5.157
Authors: F R Khuri; H Wu; J J Lee; B L Kemp; R Lotan; S M Lippman; L Feng; W K Hong; X C Xu Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Martin J Edelman; Xiaofei Wang; Lydia Hodgson; Richard T Cheney; Maria Q Baggstrom; Sachdev P Thomas; Ajeet Gajra; Erin Bertino; Karen L Reckamp; Julian Molina; Joan H Schiller; Kisha Mitchell-Richards; Paula N Friedman; Jon Ritter; Ginger Milne; Olwen M Hahn; Thomas E Stinchcombe; Everett E Vokes Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544
Authors: Jocelyn Reader; Amy K Harper; Teklu Legesse; Paul N Staats; Olga Goloubeva; Gautam G Rao; Amy Fulton; Dana M Roque Journal: Cancers (Basel) Date: 2019-10-18 Impact factor: 6.639